UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 6-K
_____________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2020
Commission File Number: 001-38283
_____________________________
InflaRx N.V.
(Translation of registrant's name into English)
_____________________________
Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)
_____________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFLARX N.V.
On January 16, 2020, in connection with a conference held by J.P. Morgan, InflaRx N.V. (the “Company”) updated and presented its corporate presentation (the “Corporate Deck”).
The Corporate Deck is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The Corporate Deck is also available on the Company’s website located at www.inflarx.de, and the presentation will be available both live and in recorded form on the Company’s website, as well.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
INFLARX N.V. | ||
Date: January 16, 2020 | By: | /s/ Niels Riedemann |
Name: | Niels Riedemann | |
Title: | Chief Executive Officer |
3
EXHIBIT INDEX
Exhibit | Description of Exhibit | |
InflaRx N.V. January 2020 Corporate Presentation titled “Controlling Inflammation” |
4